Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds

Journal of Hepatology

Volumn 62, Issue 6, 2015, Pages 1412-1419

  Xu, Chengfu ^a   Wan, Xingyong ^a   Xu, Lei ^a   Weng, Honglei ^b   Yan, Ming ^c,d   Miao, Min ^e   Sun, Yan ^c,d   Xu, Genyun ^a   Dooley, Steven ^b   Li, Youming ^a   Yu, Chaohui ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e Zhenhai Lianhua Hospital   (China)

Author keywords

Fatty liver; Hyperuricemia; NLRP3 inflammasome; Uric acid; Xanthine oxidase

Indexed keywords

ALLOPURINOL; CRYOPYRIN; FATTY ACID; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; TRIACYLGLYCEROL; URIC ACID; XANTHINE OXIDASE; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY LIVER; FEMALE; FOLLOW UP; HEPG2 CELL LINE; HUMAN; HYPERURICEMIA; IN VITRO STUDY; KIDNEY FUNCTION; LIPID DIET; LIPID STORAGE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REMISSION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; COMPLICATION; DISEASE MODEL; ENZYMOLOGY; GENE SILENCING; GENETICS; LIPID METABOLISM; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

ADULT; ANIMALS; CARRIER PROTEINS; COHORT STUDIES; DISEASE MODELS, ANIMAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; HYPERURICEMIA; INFLAMMASOMES; LIPID METABOLISM; MALE; MICE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; RISK FACTORS; URIC ACID; XANTHINE OXIDASE;

EID: 84929606132     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.01.019     Document Type: Article

References (44)

1. M. Lazo, and J.M. Clark The epidemiology of nonalcoholic fatty liver disease: a global perspective Semin Liver Dis 28 2008 339 350
2. J.G. Fan, and G.C. Farrell Epidemiology of non-alcoholic fatty liver disease in China J Hepatol 50 2009 204 210
3. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, and K. Cusi The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
4. G.C. Farrell, and C.Z. Larter Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 43 2006 S99 S112
5. N. Rafiq, C. Bai, Y. Fang, M. Srishord, A. McCullough, and T. Gramlich Long-term follow-up of patients with nonalcoholic fatty liver Clin Gastroenterol Hepatol 7 2009 234 238
6. B.Q. Starley, C.J. Calcagno, and S.A. Harrison Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection Hepatology 51 2010 1820 1832
7. R.J. Wong, R. Cheung, and A. Ahmed Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59 2014 2188 2195
8. E. Fabbrini, S. Sullivan, and S. Klein Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications Hepatology 51 2010 679 689
9. M. Hamaguchi, T. Kojima, N. Takeda, T. Nakagawa, H. Taniguchi, and K. Fujii The metabolic syndrome as a predictor of nonalcoholic fatty liver disease Ann Intern Med 143 2005 722 728
10. T.W. Yoo, K.C. Sung, H.S. Shin, B.J. Kim, B.S. Kim, and J.H. Kang Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome Circ J 69 2005 928 933
11. Y. Li, C. Xu, C. Yu, L. Xu, and M. Miao Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study J Hepatol 50 2009 1029 1034
12. J.C. Sirota, K. McFann, G. Targher, R.J. Johnson, M. Chonchol, and D.I. Jalal Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey Metabolism 62 2013 392 399
13. Y.J. Lee, H.R. Lee, J.H. Lee, Y.H. Shin, and J.Y. Shim Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults Clin Chem Lab Med 48 2010 175 180
14. I.C. Hwang, S.Y. Suh, A.R. Suh, and H.Y. Ahn The relationship between normal serum uric acid and nonalcoholic fatty liver disease J Korean Med Sci 26 2011 386 391
15. C. Xu, C. Yu, L. Xu, M. Miao, and Y. Li High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study PLoS One 5 2010 e11578
16. S. Ryu, Y. Chang, S.G. Kim, J. Cho, and E. Guallar Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men Metabolism 60 2011 860 866
17. T. Yamada, S. Suzuki, M. Fukatsu, T. Wada, T. Yoshida, and T. Joh Elevated serum uric acid is an independent risk factor for nonalcoholic fatty liver disease in Japanese undergoing a health checkup Acta Gastroenterol Belg 73 2010 12 17
18. R. Harrison Physiological roles of xanthine oxidoreductase Drug Metab Rev 36 2004 363 375
19. R. Harrison Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33 2002 774 797
20. M. Kurosaki, M. Li Calzi, E. Scanziani, E. Garattini, and M. Terao Tissue- and cell-specific expression of mouse xanthine oxidoreductase gene in vivo: regulation by bacterial lipopolysaccharide Biochem J 306 1995 225 234
21. K.J. Cheung, I. Tzameli, P. Pissios, I. Rovira, O. Gavrilova, and T. Ohtsubo Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity Cell Metab 5 2007 115 128
22. A. Kushiyama, H. Okubo, H. Sakoda, T. Kikuchi, M. Fujishiro, and H. Sato Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development Arterioscler Thromb Vasc Biol 32 2012 291 298
23. J.C. Leemans, S.L. Cassel, and F.S. Sutterwala Sensing damage by the NLRP3 inflammasome Immunol Rev 243 2011 152 162
24. K. Schroder, R. Zhou, and J. Tschopp The NLRP3 inflammasome: a sensor for metabolic danger? Science 327 2010 296 300
25. F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, and J. Tschopp Gout-associated uric acid crystals activate the NALP3 inflammasome Nature 440 2006 237 241
26. J. Tschopp, and K. Schroder NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10 2010 210 215
27. B. Vandanmagsar, Y.H. Youm, A. Ravussin, J.E. Galgani, K. Stadler, and R.L. Mynatt The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance Nat Med 17 2011 179 188
28. R. Stienstra, J.A. van Diepen, C.J. Tack, M.H. Zaki, F.L. van de Veerdonk, and D. Perera Inflammasome is a central player in the induction of obesity and insulin resistance Proc Natl Acad Sci U S A 108 2011 15324 15329
29. J. Henao-Mejia, E. Elinav, C. Jin, L. Hao, W.Z. Mehal, and T. Strowig Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity Nature 482 2012 179 185
30. Y.G. Wang, W.L. Fang, J. Wei, T. Wang, N. Wang, and J.L. Ma The involvement of NLRX1 and NLRP3 in the development of nonalcoholic steatohepatitis in mice J Chin Med Assoc 76 2013 686 692
31. M. Lazo, R. Hernaez, S. Bonekamp, I.R. Kamel, F.L. Brancati, and E. Guallar Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study BMJ 343 2011 d6891
32. Z.M. Younossi, M. Stepanova, F. Negro, S. Hallaji, Y. Younossi, and B. Lam Nonalcoholic fatty liver disease in lean individuals in the United States Medicine 91 2012 319 327
33. Y.Y. Sautin, T. Nakagawa, S. Zharikov, and R.J. Johnson Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress Am J Physiol Cell Physiol 293 2007 C584 C596
34. Y. Ogura, F.S. Sutterwala, and R.A. Flavell The inflammasome: first line of the immune response to cell stress Cell 126 2006 659 662
35. B.K. Davis, H. Wen, and J.P. Ting The inflammasome NLRs in immunity, inflammation, and associated diseases Annu Rev Immunol 29 2011 707 735
36. N. Esser, L. L'Homme, A. De Roover, L. Kohnen, A.J. Scheen, and M. Moutschen Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue Diabetologia 56 2013 2487 2497
37. S.L. Masters, A. Dunne, S.L. Subramanian, R.L. Hull, G.M. Tannahill, and F.A. Sharp Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes Nat Immunol 11 2010 897 904
38. T. Jourdan, G. Godlewski, R. Cinar, A. Bertola, G. Szanda, and J. Liu Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes Nat Med 19 2013 1132 1140
39. H. Xiao, M. Lu, T.Y. Lin, Z. Chen, G. Chen, and W.C. Wang Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility Circulation 128 2013 632 642
40. R. Zhou, A.S. Yazdi, P. Menu, and J. Tschopp A role for mitochondria in NLRP3 inflammasome activation Nature 469 2011 221 225
41. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2002 1221 1231
42. T. Ohtsubo, I.I. Rovira, M.F. Starost, C. Liu, and T. Finkel Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2 Circ Res 95 2004 1118 1124
43. P.S. Hsieh, J.S. Jin, C.F. Chiang, P.C. Chan, C.H. Chen, and K.C. Shih COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver Obesity (Silver Spring) 17 2009 1150 1157
44. G. Panasyuk, C. Espeillac, C. Chauvin, L.A. Pradelli, Y. Horie, and A. Suzuki PPARgamma contributes to PKM2 and HK2 expression in fatty liver Nat Commun 3 2012 672